A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
Completed
Pfizer
Phase 3
2006-12-01
The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with
placebo for treating moderate to severe chronic pain over a 12 week period.
The purpose of the research study is to find out if opioid dependent chronic pain patients
who are judged by their physician to be eligible to change their current opioid medicine and
to participate in this study can be successfully adjusted to a stable dose of EMBEDA
(morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's
risk for prescription opioid abuse, misuse and diversion.
Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions
Completed
Ranbaxy Inc.
Phase 1
2006-10-01
The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide
from 2 tablet products and determine if the 2 products were bioequivalent to each other.
Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions
Completed
Ranbaxy Inc.
Phase 1
2006-10-01
The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide
from 2 tablet products and determine if the 2 products were bioequivalent to each other.
Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain
Terminated
Pfizer
Phase 4
2015-04-24
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine
sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
